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Abstract 
Dengue virus belongs to the Flaviviridae family which also includes viruses such as the Zika, West 
Nile and yellow fever virus. Dengue virus generally causes mild disease, however, more severe 
forms of the dengue virus infection, dengue haemorrhagic fever (DHF) and dengue haemorrhagic 
fever with shock syndrome (DSS) can also occur, resulting in multiple organ failure and even death, 
especially in children. The only dengue vaccine available in the market, CYD-TDV offers limited 
coverage for vaccinees from 9-45 years of age and is only recommended for individuals with prior 
dengue exposure. A number of mutations that were shown to attenuate virulence of dengue virus in 
vitro and/or in vivo have been identified in the literature. The mutations which fall within the 
conserved regions of all four dengue serotypes are discussed. This review hopes to provide 
information leading to the construction of a live attenuated dengue vaccine that is suitable for all 
ages, irrespective of the infecting dengue serotype and prior dengue exposure. 
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Introduction 
Dengue virus (DENV) causes approximately 390 
million infections per year, of which 100 million are 
symptomatic infections and 25,000 deaths occur 
annually, mainly in children [1]. Classified in the 
same mosquito-borne Flaviviridae family along with 
the emerging pathogenic viruses such as West Nile 
virus and Zika virus, DENV also serves as a model 
organism to facilitate the study of these relatively 
less-characterised viruses. DENV is endemic in more 
than 125 countries spanning across South-East Asia, 
Western Pacific, East Mediterranean, Africa, and the 
Americas [2]. In South-East Asian countries such as 
Malaysia, Indonesia and the Philippines, it is of 
utmost importance to lessen the DENV disease 
burden as DENV infections have reached epidemic 
proportion. The DENV mosquito vectors, Aedes 
aegypti and Aedes albopictus, are also spreading from 
the tropical and sub-tropical regions to more 
temperate areas due to global warming [3]. Therefore, 
it is now more relevant than ever to find an effective 
prevention strategy against DENV infections and one 
such strategy is by developing a new live attenuated 
vaccine which will overcome the limitations 
encountered by the current licensed DENV vaccine in 
the market and those under development. 
Current DENV vaccine in the market 
The first dengue vaccine, CYD-TDV or 
Dengvaxia®, developed by Sanofi-Pasteur, is a 
tetravalent, recombinant live attenuated vaccine 
(LAV) with a yellow fever 17D virus backbone. The 
four chimeric yellow fever 17D vaccine viruses were 
engineered to express the surface E (envelope) and 
prM (membrane) proteins of each of the four 
serotypes of dengue virus [4]. In the third year of 
phase 3 CYD-TDV trial in Asia (the CYD14 trial), there 
was an excess of hospitalisations for dengue among 
vaccinated children aged 2 to 5 years [5]. This raised 
the concern about the potential effects of baseline 
dengue serostatus and age of the vaccinees on the 
vaccine safety and efficacy. Nevertheless, CYD-TDV 








December 2015 and as of late 2017, was licensed in 19 
countries [6]. 
CYD-TDV is administered in a 3-dose schedule 
at 6-month intervals and the vaccine has been licensed 
for individuals aged 9 to 45 years living in dengue 
endemic areas, although both upper and lower age 
limits might vary by license. Currently, CYD-TDV is 
mainly available in the private market except in Brazil 
and the Philippines, whereby the vaccine was 
included in their national immunisation programs [7]. 
There are multiple issues and controversies 
surrounding the administration of this vaccine. The 
Philippines government has discontinued its 
CYD-TDV vaccination program after a number of 
deaths in children is allegedly linked to CYD-TDV 
being administered to these children who had no 
prior dengue infection. Indeed, after 61 months of 
follow up, Sanofi released new results based on a 
specifically developed NS1 assay and found that the 
administration of CYD-TDV increased the risk of 
hospitalization for dengue in seronegative vaccine 
recipients compared to controls [8]. By April 2018, 
WHO issued a report which recommended that the 
vaccine be administered only to persons who have 
had a prior dengue infection [6]. 
The requirement for three doses of CYD-TDV 
indicated that the immune response to the primary 
dose of the vaccine was weak. This is most likely due 
to the fact that CYD-TDV is composed largely of 
genome sequence derived from the yellow fever virus, 
and only contained some DENV surface proteins. 
CYD-TDV also lacked DENV NS1, an immunogenic 
viral protein secreted at high levels in infected 
individuals that has been hypothesised to contribute 
directly to disease pathogenesis [9]. An immune 
response to NS1 might be essential to protect against 
DENV. With the apparent lack of T cell epitopes from 
the non-structural proteins in the CYD-TDV, it is 
predicted that only neutralising antibodies would be 
generated in the vaccines while the essential 
protective T cell response is missing [10]. All these 
factors have been stipulated to contribute to the 
CYD-TDV-enhance disease outcome in seronegative 
vaccines [11]. 
Current DENV vaccines in Phase 3 trials 
Two other tetravalent LAVs, Takeda’s TDV and 
National Institutes of Health (NIH)/Butantan 
Institute’s TV003, are undergoing phase 3 trials [12]. 
TDV consists of attenuated virus with three point 
mutations (each within the 5’UTR, NS1 and NS3, 
respectively) in its genome [13]. In Phase 1 studies, 
following immunisation with TDV, 62% participants 
seroconverted in response to all four serotypes while 
96% participants seroconverted in response to at least 
three dengue virus serotypes [14]. In Phase 2 studies, 
the two-dose, three-months apart regimen is 
supported. In participants who were seronegative at 
baseline, a second dose administered three months 
later resulted in 86% seroconversion in response to all 
four serotypes compared to 69% in a group which had 
received only one dose of the vaccine [15]. Takeda has 
now completed its target vaccinations of 20,000 
children and adolescents aged 4 through 16 and 
preliminary outcomes for these Phase 3 studies are 
expected by the end of 2019 [16]. 
The TV003 is comprised of DENV-1, DENV-3, 
DENV-4 and a chimeric DENV-2 which all carried a 
30-nucleotide deletion in the 3’ UTR of its genome 
[17]. Previously, the vaccine provided robust and 
balanced immune responses to all four serotypes by 
inducing a tetravalent antibody response in 74% of the 
healthy, flavivirus-naïve participants, with 92, 76, 97, 
and 100% of the vaccinees seroconverting in response 
to DENV-1, DENV-2, DENV-3, and DENV-4, 
respectively [18]. In the follow up study, the ability of 
a single dose of TV003 to protect against DENV 
challenge was evaluated. After a single dose of TV003, 
followed by challenge with the DENV-2 virus 
rDEN2D30 six-month post-vaccination, all 21 
recipients were protected from infection by 
rDEN2D30. In contrast, 100% of the 20 placebo 
recipients who were challenged with rDEN2D30 
developed viraemia, 80% developed rash, and 20% 
developed neutropenia. [19]. Additionally, TV003 
induced 87% seroconversion in response to all four 
serotypes of DENV in participants with prior 
flavivirus exposure. However, it is unknown whether 
the induced neutralising antibodies recorded were 
sufficient to confer protection against natural dengue 
infection. The mean peak antibody titres of the 
recruited individuals also gradually declined 
six-month post-vaccination although not to as low as 
the baseline levels [20]. An estimated 16,944 subjects 
aged 2 to 59 years old are currently being recruited for 
the Phase 3 trial to evaluate the efficacy and safety of 
TV003 (ClinicalTrials.gov Identifier: NCT02406729). 
It was also noted that due to the DENV-2 component 
being less immunogenic than the other serotypes in 
TV003, TV005 was formulated to have exactly the 
same formulation as TV003 except that it contained 
ten times more of the DENV-2 component [18]. TV005 
has yet to progress to Phase 3 trials although it has 
shown promising results in terms of its magnitude of 
immune response, HLA restriction and antigen 
specificity [21]. The TV003/TV005 vaccine is planned 
to be administered as a single subcutaneous dose. 
For TDV, the genetic stability of the three point 
mutations (5’ UTR-57, C to T; NS1-53 glycine to 
aspartate; NS3-250 glutamate to valine) is of concern. 




The 5‘UTR-57-T showed high propensity of reversion 
to the pathogenic wild type at very low passage 
numbers (as few as ten passages) [22]. Due to the 
limited number of mutations in TDV, there is a strong 
possibility that the attenuated vaccine strain could 
revert to its wild type form [23]. The genetic stability 
of the 30-nucleotide deletion in TV003/TV005 vaccine 
is not yet evaluated, however the vaccine has 
encountered a potential setback as lower 
seroconversion rate in African Americans (57%) was 
recorded following administration of the vaccine 
when compared to non-African Americans (86%) [24]. 
Construction of the TDV vaccine strain through 
attenuation has been achieved through serial passages 
of the wild type virus in cell lines, in particular using 
primary dog kidney (PDK) cells [25]. These 
attenuated strains have been tested separately for 
safety and immunogenicity before being formulated 
into a tetravalent product. Unfortunately, it appeared 
that once formulated into tetravalent vaccines, some 
level of interference between the virus strains 
occurred, leading to a dampened or adverse immune 
response for some DENV serotypes as compared to 
the monovalent vaccine candidates [26]. For example, 
DENV-3 vaccine strain DENV-3 PGMK30 was 
generated by passaging the wild type DENV-3 16562 
thirty times in primary green monkey kidney cells 
and three times in primary fetal rhesus lung cells. In a 
human safety trial, however, all volunteers who 
received the tetravalent formulation containing 
PGMK30 developed symptoms and signs consistent 
with acute dengue, with detectable DENV-3 viraemia 
[27]. Following the disappointing clinical trial results, 
this DENV-3 vaccine strain was further passaged in 
Vero cells using the same protocol to yield the 
Vero-derived Vaccine (VDV3) strain, which showed 
attenuation as the PGMK30 strain previously. When 
VDV3 was administered to healthy volunteers, it 
again caused disease in recipients [28, 29]. 
Hence, understanding the exact molecular 
determinants of virulence that contributed to these 
divergent clinical outcomes despite the observed 
attenuation in vitro could enable a more objective and 
accurate approach in selecting attenuated strains for 
development into LAVs. Notably, CYD-TDV as the 
only licensed vaccine against DENV is not approved 
for children younger than 9 years and children are the 
main age group which is the most vulnerable to 
DENV infection. The need remains for a vaccine that 
is safe and effective in recipients of all ages, especially 
those younger than 9 years. In summary, an ideal 
DENV vaccine should be safe for both seronegative 
and seropositive individuals, attenuated in such a 
way that is stable with no possibilities of reversion to 
its wild type phenotype and be sufficiently 
immunogenic to confer long-life protection and broad 
protection against all four DENV serotypes. 
Therefore, the identification of molecular determi-
nants of DENV virulence within the conserved 
regions of the genomes of all four DENV serotypes 
will aid in vaccine design. Such considerations when 
constructing the next LAV against dengue is more 
likely to confer a balanced and protective immunity 
against DENV, independent of its serotypes and be 
capable of inducing high seroconversion in vaccinees, 
irrespective of prior dengue exposure [30, 31]. 
The molecular determinants of virulence 
in dengue virus 
The four antigenically-distinct dengue virus 
serotypes, DENV-1 to 4, share 60 to 70% genetic 
homology [32]. Initial infections with any of the four 
DENV serotypes only raise protective serotype- 
specific antibodies. The dominant population of 
antibodies against one DENV serotype, while cross- 
reactive, are non-neutralising towards other DENV 
serotypes [33]. This contributes to the manifestation of 
a more severe disease if one is to be re-infected by a 
heterologous DENV serotype, a phenomenon known 
as antibody dependent enhancement (ADE) of 
dengue infection. Indeed, ADE is thought to be the 
underlying reason as to why there is a high rate of 
infants showing severe dengue disease during their 
first dengue infection as the levels of maternal 
polyclonal dengue antibodies would start to wane 
after birth [34, 35]. 
DENV morphology and genome 
organisation 
All flaviviruses including DENV share a similar 
organisation of the virion and genomic structure [36]. 
Each virion is spherical in shape, enveloped and about 
50 nm in size. DENV envelope is comprised of the 
envelope (E) protein which is organised into dimers 
and the membrane (M) protein which is cleaved from 
the immature prM protein by the host protease, furin. 
Inside the envelope is the nucleocapsid, which 
consists of multiple copies of the capsid (C) protein 
and the viral genome. The viral genome is a 10.7 
kilobase, positive-sense, single- stranded, capped 
RNA (+ssRNA). The viral proteins are encoded in a 
single open reading frame (ORF) that is co- and 
post-translationally cleaved by viral and host 
proteases and is flanked by 5′ and 3′ untranslated 
regions (UTRs). Overall, the ORF encodes for three 
structural proteins (C, prM, E), and seven 
non-structural (NS) proteins [37]. 
Genetic comparisons of strains with varying 
degrees of pathogenicity have revealed differences in 




the nucleotide and polyprotein sequences, suggesting 
that they play a role in virulence. Here we present the 
specific molecular determinants within the DENV 
genome and the amino acids of the DENV polyprotein 
that appear to have a significant role in virulence, 
either in vitro and in vivo. These are only discussed 
here if they are highly conserved in all four serotypes 
and are not included in the Sanofi Pasteur CYD-TDV, 
Takeda TDV and NIH TV003/TV005 vaccines. Any 
mutations that are known and tested to be unstable, 
led to replicative-defective phenotype and secondary 
mutations to arise are not included in this review as 
these mutations are not going to be suitable for a LAV 
development. 
5’ untranslated region (5’ UTR) 
The non-coding 5' untranslated region (5' UTR) 
spans approximately 100 nucleotides and shows 
almost complete sequence conservation among the 
four serotypes [38]. The identified elements within the 
5’ UTR include the large 5' stem loop A (5' SLA) and 
the short 5' stem loop B (5' SLB) which ends in the 
translation initiation AUG codon [39, 40]. These 
elements have been shown to be required for virus 
replication, translation and pathogenesis. For 
instance, SLA was shown to be necessary for the 
correct positioning of the NS5 RNA polymerase 
before the initiation of RNA synthesis [41]. On the 
other hand, SLB contains a sequence known as 5′ UAR 
(Upstream AUG Region) that is complementary to a 
sequence located at the 3′ UTR of the viral genome 
[42]. 
Sirigulpanit et al. [43] demonstrated that DENV 
with a single substitution mutation at nucleotide 
position 69 from A to U, contributed to a lower 
mortality rate in mice, but yielded similar plaque size 
compared to the wild type. The nucleotide at position 
69 is located within the region in between SLA and 
SLB of the 5’ UTR. Previously, Leitmeyer et al. [44] 
discovered that the same exact substitution mutation 
from A to U at the nucleotide position 69 in the 5' UTR 
was among the changes that distinguished the more 
virulent South-East Asian genotype from the 
American genotype. Despite the fact that the 
sequences obtained from the first 68 nucleotides were 
identical among the two strains, those belonging to 
the American genotype had a different nucleotide at 
positon 69. This is predicted to change the secondary 
structure, resulting in a reduced stem length, and a 
longer 39-terminal loop of 12 nucleotides compared to 
the more virulent Southeast Asian genotype. Next, 
Cahour et al. [40] showed that deletion of nucleotides 
from position 82-87 which resides within the SLB in 
the 5' UTR yielded viable viruses with reduced 
translation efficiency. The growth-restricted mutant 
progeny produced small plaques in simian LLC-MK2 
cells but failed to produce any plaque in mosquito 
C6/36 cells. 
Capsid (C) 
The C protein contains a flaviviral-conserved 
internal hydrophobic domain which may be 
associated with the host ER membrane. This 
interaction is thought to facilitate the assembly and 
the entry of the virus into the lumen of host ER as 
virions. The removal of the internal hydrophobic 
region of protein C at amino acid positions 42-59 led 
to a significant attenuation in the suckling mice and 
this is likely due to the disruption in the assembly of 
infectious viral particles [45]. 
Within the capsid-coding region lies a stem-loop 
structure known as the capsid-coding region hairpin 
element (cHP). cHP enhances translation start codon 
selection and is required for viral replication [46]. 
Clyde et al. [47] showed that any mutations that 
disrupt cHP are rescued by spontaneous 
compensatory mutations that restabilised the cHP 
structure. One such mutation is at nucleotide position 
204, located well downstream of the cHP. At this 
position, A is substituted into G with no change in the 
resulting amino acid sequence. Although the cHP 
structure was rescued, the A204G infectious clone 
retained a defect in viral replication [47]. 
Pre-membrane/membrane (prM/M) 
Pryor et al. [48] introduced a number of 
mutations at amino acid residue position 39 in the 
prM coding region. Comparison of M protein 
sequences of 40 flaviviruses revealed that a polar 
amino acid is always present at position 39. For 
DENV-1, -2 and -3, the residue at M-39 is histidine, 
whereas for DENV-4 and all other flaviviruses, it is 
asparagine. They found that a substitution of the 
histidine residue with the basic amino acid arginine in 
the DENV-2 genome resulted in a moderate but 
significant (∼2 log10) reduction in virus titre. A 
substitution of histidine-39 with uncharged polar 
amino acid glutamine was also shown to severely 
decrease viral replication [48]. Indeed, a histidine to 
arginine substitution at residue 39, in addition to two 
changes in the E protein, was identified in a chimeric 
DENV-1/yellow fever virus and it caused decreased 
viraemia in monkeys compared to the parental 
DENV-1 and yellow fever virus [49]. 
After proteins required for virus assembly are 
translated, the prM forms heterodimers with E 
protein intracellularly before immature virus particles 
can be secreted [50]. The C-terminus of prM protein is 
consisted of an α-helical domain (MH) (residues 113 
to 128), followed by two transmembrane domains 




(MT1 and MT2) [51]. The role of nine highly 
conserved MH residues in the replication cycle of 
DENV in a DENV-1 prME expression construct was 
investigated by Hsieh et al. [52]. Alanine substitutions 
on all nine residues studied except for alanine 
substitution on residue 112 were found to impair prM 
to M cleavage by furin and therefore, would lead to 
the production of non-infectious virus-like particles 
(VLPs) [53]. VLPs have been proposed to be 
promising vaccine candidates against flaviviruses 
such as Murray Valley encephalitis virus [54] and also 
DENV [55]. However, for the purpose of LAVs 
development, mutations that led to the production of 
VLPs are not suitable as an attenuation method as 
VLPs will not be able to replicate in the host. 
Interestingly, one out of the nine mutants constructed 
by Hsieh et al. [52] which had a substitution of serine 
to alanine at position 112 within the M polypeptide 
demonstrated impaired viral assembly. The mutation 
did not affect the prM cleavage and replicon particle 
entry, making it an ideal mutation to be incorporated 
into a DENV LAV strain [52]. 
Envelope (E) 
The E glycoprotein, situated on the surface of the 
dengue virion, is responsible for virus attachment, 
virus-specific membrane fusion in acidic pH 
endosomes, and subsequent virus assembly. Butrapet 
et al. [56] engineered fifteen mutant dengue viruses to 
identify amino acids in one of the molecular hinges of 
the envelope protein that are critical for viral 
infection. One such amino acid is an alanine residue at 
position 54 which is also conserved in all flaviviruses. 
Mutation of alanine to valine at residue 54 from the 
wild type yellow fever French viscerotropic virus in 
the French neurotropic vaccine (FNV) strain was 
postulated to be one of the E protein mutations 
contributing to the attenuation phenotype of FNV [57, 
58]. Therefore, Butrapet et al. [56] substituted the 
small hydrophobic residue alanine with the large 
acidic residue glutamic acid. This mutation resulted in 
a shifted fusion threshold to a higher pH and caused 
slightly delayed replication in Vero cells, suggesting 
alanine-54 might be important for stabilisation of the 
functional hinge structure. Additionally, threonine at 
position 280 was also targeted for a substitution with 
a much larger tyrosine. This led to altered fusion 
threshold to a slightly lower pH and the mutant 
showed significantly lower fusion capacity than the 
wild type virus [56]. 
Huang et al. [59] conducted a comprehensive 
study of the E protein which is known to direct 
virus-mediated membrane fusion. They introduced 27 
mutations into the fusion peptide of an infectious 
cDNA clone of DENV-2 and recovered seven stable 
mutant viruses. The fusion efficiency of the mutants 
was impaired, demonstrating the requirement for 
specific fusion peptide amino acids for optimal fusion. 
The mutant viruses (G102S, G104S, F108W) exhibited 
different growth kinetics and/or genetic stabilities in 
different cell types and adult mosquitoes. Virus 
particles could be recovered following RNA 
transfection of cells with five mutants (W101F, L107A, 
F108A and WF101, 108FW); however, recovered 
viruses could not re-infect cells. These viruses could 
enter cells, but internalised virus appeared to be 
trapped in endosomal compartments of infected cells, 
thus suggesting a fusion blockade. 
The ability of DENV to escape the endosome and 
release its nucleocapsid into the cytoplasm for 
replication prior to lysosomal degradation is critical 
during virus entry via clathrin-mediated endocytosis 
in non-ADE infection. However, during ADE of 
DENV infection however, virus-antibody complexes 
binding to FcγR is thought to allow the virus antibody 
complexes to enter cells through phagocytosis. As 
virions that enter by FcγR-mediated phagocytosis 
would still eventually enter the endosomal/lysosomal 
pathway, viral-endosomal membrane fusion is likely 
necessary for the infectivity of virus-antibody compl-
exes [60]. Therefore, Chotiwan et al. [61] used several 
DENV-2 E protein mutants to identify molecular 
determinants critical for virus-immune complex entry 
via FcγRIIA-bearing human myelogenous K562 cells 
and monkey CV-1 fibroblasts constitutively 
expressing transfected human FcγRIIA. Indeed, using 
two temperature-sensitive, fusion-defective mutant 
viruses carrying mutations (G104S and L135G) 
targeted to affect different steps in fusion, they 
demonstrated that the DENV E protein conformation- 
mediated membrane fusion is critical for infectivity 
under both ADE and non-ADE conditions.  
The flexible molecular hinges of the envelope 
protein as mentioned earlier is important for virion 
assembly and entry, specifically as it enables the 
correct conformational changes of the E protein to 
occur for fusion and maturation process [62, 63]. 
Initially, Goo et al. [64] found that a T198F mutation in 
the envelope protein of West Nile virus resulted in a 
~70-fold increase in sensitivity to neutralization by a 
monoclonal antibody, E60. This monoclonal antibody 
is known to target a cryptic epitope that is normally 
poorly accessible [65]. Therefore, it follows that the 
epitope was exposed more in the T198F mutant, 
leading to reduced virus stability at physiological 
temperatures. Based on sequence homology, the 
threonine at residue 198 in West Nile virus 
corresponds to a phenylalanine residue in DENV at 
position 193. The introduction of the reciprocal 
mutation F193T in the Western Pacific strain of 




DENV-1 led to ~10-fold reduction in the infectivity 
and ~3-fold reduction in the half-life of the virus 
particles. Similar to results with WNV T198F, the 
mutant DENV-1 F193T was more sensitive to 
neutralization by the monoclonal antibody E60 than 
the wild type viruses. Hence, it appears that a single 
point mutation at a molecular hinge of the E protein of 
two flaviviruses, DENV and West Nile virus, can alter 
the E protein conformation such that the mutant 
viruses became less virulent and stable. More 
importantly, the T198F change in the West Nile virus 
resulted in the attenuated phenotype in mice, 
therefore, it will be imperative to investigate whether 
this also applies to DENV [64]. 
NS proteins 
The DENV NS proteins, except for NS5, are 
integral membrane proteins. Flavivirus NS1 is a 48 
kDa glycoprotein which is composed of five 
transmembrane domains that is translocated into the 
ER lumen co-translationally [66]. NS1 plays an array 
of functions. Aside from facilitating virus replication, 
it can also be secreted and is thought to help the virus 
evade the immune system [67, 68]. NS1 also 
modulated early events in viral RNA replication and 
was shown to co-localise with double stranded RNA 
(dsRNA) and interacted with the NS4B [69]. More 
recently, it was demonstrated that NS1 interacted 
with the E glycoproteins presumably on the surface of 
virions and these interactions were required for 
efficient production of infectious virus particles [70].  
In the infected cell, NS1 is bound to the 
membrane of the ER vesicles on the lumen side and 
dimerises upon the addition of high-mannose 
carbohydrates to help anchoring the viral replication 
complex. The NS1 dimer contains three domains; a 
small β-roll domain, a Wing domain, and a β-ladder 
domain [71]. Scaturro et al. [70] selected 46 residues 
for alanine scanning mutagenesis and found that 
alanine substitutions at position S114, W115, D180 or 
T301 of NS1 altered the production of infectious virus. 
Specifically, the mutants showed minor effects of viral 
RNA replication, but the virus production was greatly 
impaired. The mutants also had reduced intracellular 
and extracellular infectivity. The study supported the 
notion that NS1 is a critical determinant for the 
assembly or release of infectious virus particles.  
Both NS2A and NS2B are very poorly 
characterised so far. Mis-cleavage between NS1 and 
NS2A could affect viral RNA replication, and 
mutations in the protein was observed to affect virion 
assembly. A mutagenesis study revealed that several 
NS2A mutations, G11A, E20A, E100A, Q187A, and 
K188A, impaired virion assembly without specifically 
affecting viral RNA synthesis [72]. In addition, the 
NS2A protein of DENV has eight predicted 
transmembrane segments. By introducing a series of 
triple alanine substitutions, Wu et al. (2017) created 
six NS2A mutants with mutations within the 
transmembrane segment, one to two of which 
displayed novel phenotype. These mutants showed a 
>1,000-fold reduction in virus yield and were unable 
to form plaques despite having wild type-levels of 
viral replication and no defects in virus assembly and 
secretion. One of the mutants, NM-5, had alanines 
replacing the semi-conserved alanine-lysine-phenyl-
alanine residues. Overall, the findings suggest that the 
amino acid sequence of the N-terminal half of DENV2 
NS2A is critical for viral RNA synthesis and 
cytopathic effects [73]. NS2B is a cofactor for NS3 
protease and it co-localises with dsRNA, NSI, NS3, 
and NS5 within the replication complex. A 
40-amino-acid segment of NS2B (DENV-4 amino 
acids 1396 to 1435) comprising a hydrophilic domain 
surrounded by hydrophobic regions was found to be 
essential for NS2B-NS3 serine protease activity [74]. 
NS3 has two domains: the protease lies at the 
N-terminal end and requires the NS2B cytoplasmic 
loop [75, 76] while the C-terminal domain of NS3 
possesses the helicase activity that presumably 
unwinds double-stranded RNA along with an ATPase 
activity involved in the capping of the newly 
synthetized genomic RNA [77, 78]. Blaney et al. [79] 
analysed the recombinant DENV-4 viruses which 
were temperature sensitive and found that they 
yielded small plaques and were attenuated in the 
suckling mice. One of the mutants was a NS3 mutant 
with a substitution at position 192 from aspartic acid 
to asparagine. Additionally, this mutant was also 
found to confer a greater than 10,000-fold reduction in 
replication of the recombinant virus in SCID mice 
transplanted with HuH-7 cells [79]. 
NS4A contains two transmembrane domains 
and the first 48 amino acids of DENV-2 NS4A were 
reported to form an amphipathic helix that mediates 
oligomerisation [80, 81]. NS4A is thought to act as a 
scaffold for the replication complex and is proposed 
to induce membrane alterations. Following nuclear 
magnetic resonance analysis, Lee et al. [82] 
constructed alanine substitutions for 15 flaviviruses 
with conserved NS4A residues and found that two 
amino acids located within the first transmembrane 
domain are important for viral replication, NS4A 
oligomerisation and stability. On the other hand, 
NS4A also interacted with NS4B in virus-infected cells 
and in three other NS4A mutants, L48A, T54A, and 
L60A with disrupted NS4A-NS4B interactions, 
abolished or severely reduced viral replications were 
demonstrated [83]. 





Table 1. Nucleotide and amino acid changes in the genome of DENV that contributes to virulence.  
 Region of 
genome 
Position in the genome Mutation Effects of the mutation References 
1 5’ UTR Nucleotide 69 in DENV-2 A to T -Reduced mice mortality rate 31.25% compared to the wild type (84.37%) [43, 44] 
-Distinguished the South-East Asian genotype from the American genotype 
2 5’ UTR Nucleotide Δ(82-87) in DENV-4 6 nt deletion -Reduction in translation efficiency [40] 
-Yielded small plaques in simian LL2-MK2 cells, no plaques in C6/36 cells 
3 C Nucleotide (42-59) in DENV-2 19 nt deletion -Mutant highly attenuated in the suckling mice [45] 
4 C Nucleotide 204 in DENV-2 A to G -Reduced viral replication by at least 2.5-4.0 log units [47] 
5 pRM Amino acid 39 in DENV-2 H to R -Reduced virus titres (1.7–2.2 log10 lower than the parental virus) Decreased 
viraemia in monkeys 
[48, 49] 
6 pRM Amino acid 39 in DENV-2 H to Q -Severe effect on virus replication, with overall 5.3 log10 (33 °C) or 4.2 log10 
(37 °C) decreases in final virus titres 
[48] 
7 prM Amino acid 112 in DENV-1 S to A -Reduced the assembly of replicon particles [52] 
-Showed more than one log reduction in the amounts of replicon RNA 
8 E Amino acid 54 in DENV-2 A to E -Lower replication efficiency in Vero cells [56] 
9 E Amino acid 54 and 280 in DEV-2 A to E and T to Y -Altered the pH threshold of fusion [56] 
10 E Amino acid 102, 104 and 108 in 
DENV-2 
G to S, G to S, F to W -Reduced growth in mammalian cells at 37 °C by 2 to more than 4.6 logs [59] 
11 E Amino acid 101, 107, 108 in 
DENV-2 
W to F, L to A, F to 
A, W to F, F to W 
-Showed amplification of vRNA and viral antigen expression in V-0 
transfections, but failed to produce virus that could initiate a second round (V-1) 
of infection 
[59] 
12 E Amino acid 108 in DENV-2 F to A -Mutant was able to enter endosomes through endocytosis but unable to escape 
from the endosomal and lysosomal compartments 
[59] 
13 E Amino acid 104 and 135 in DENV-2 G to S and L to G -Deficient viral fusion activity during ADE conditions [61] 
14 E Amino acid 193 in DENV-1 F to T -Led to ~10-fold reduction in the infectivity [64] 
-Led to ~3-fold reduction in the half- life of the virus particles. 
- The mutant viruses were more sensitive to neutralization by the monoclonal 
antibody E60 than the wild type viruses 
15 NS1 Amino acid 114, 115, 180 and 301 in 
DENV-2 
S to A, W to A, D to 
A and T to A 
-Minor effects on RNA replication, but massive impairment of virus production 
(up to ~2.5 log10 reduction compared to the wild type) 
[70] 
 
16 NS2A Amino acid 11, 20, 100, 187, and 188 
in DENV-2 
G to A, E to A, E to 
A, Q to A and K to A 
-Impaired virion assembly without specifically affecting viral RNA synthesis  
17 NS2A Amino acid 31-33 ALF to AAA - Showed >1,000-fold reduction in virus yield, an absence of plaque formation 
despite wild-type-like replicon activity, and infectious- virus-like particle yields. 
[73] 
18 NS2B Amino acid 54-92 in DENV-4 40 aa deletion 
 
-Eliminated autoproteolytic activity [74] 
 
19 NS3 Amino acid 192 in DENV-4 D to N - Attenuated virulence as measured from suckling mice brain and SCID-Huh-7 
serum 
[79] 
20 NS4A Amino acid 50 and 67 in DENV-2 E to A and G to A -Reduced viral replication [82] 
 -Decreased NS4A oligomerisation 
-Reduced NS4A protein stability 
21 NS5 Amino acid 325, 519, 769, 840 and 
841 in DENV-2 
R to A, R to A, R to 
A, K to A and R to A 
-High RNA synthesis activity in vitro but delayed or impaired replication in vivo [91] 
22 NS5 Amino acid 362 and 370 in 
10418-10422 in DEN-2 
R to A and K to A -Delayed viral replication and reduced polymerase activity in vitro [91] 
23 3’ UTR Nucleotide 10336-10340 and 
10418-10422 in DEN-2 
CTAC to GATA and 
CCTG to GGAC 
-Produce shorter sfRNAs that showed reduced viral fitness in human cells, 
quickly outcompeted by strains that generate the long sfRNAs. 
[99] 
24 3’ UTR Nucleotide 10474-10478 and 
10562-10566 in DENV-2 
5 nt deletion -Reduce viral translation rate by 60% [95] 
   
Note: For 5’ UTR and 3’ UTR, the number represents the nucleotide positions on the respective DENV genome and for C to NS5, the number denotes amino acid residue 
position from the N-terminus of the respective protein. 
 
NS4B contains three transmembrane domains 
and is N-glycosylated at residues 58 and 62 [84, 85]. 
To the best of our knowledge, no stable and non-lethal 
mutations in the NS4B protein have been discovered. 
One mutant which contained a proline to leucine 
mutation in amino acid 101 of the NS4B did result in 
decreased replication in C6/36 cells relative to the 
wild type DENV-4 and decreased infectivity for 
mosquitoes. However, this mutant showed enhanced 
replication in Vero and human HuH-7 cells, and 
enhanced replication in SCID mice implanted with 
HuH-7 cells which rendered the mutation 
inappropriate to be included in a vaccine strain [86]. 
NS5 is the largest and most highly conserved 
flavivirus protein. The N terminus of NS5 contains an 
N-terminal methyltransferase domain (MTase) and it 
has been suggested that this domain is involved in the 
methylation of the 5’ cap [87]. The capping of the viral 
RNA genome is required for its stability and 
translation into viral polyproteins by host cell 
ribosomes [88]. The NS5 C-terminal contains the 
RNA-dependent RNA polymerase (RdRp) domain 
and previous studies have demonstrated that DENV 
genome cyclisation was necessary for relocating the 
promoter-NS5 complex with the RdRp formed at the 
5’ end, to the 3’ end initiation site [41]. NS5 also 
appeared to interfere with the innate antiviral cell 
response by binding and inducing STAT2 
degradation [89]. In addition, NS5 interacted with the 
viral NS3 protein by stimulating the nucleoside 
triphosphatase (NTPase) and RNA triphosphatase 
activities of NS3 [90].  




A mutational analysis of the RdRp domain of 
DENV-2 NS5, in which basic residues on the surface 
of the protein were replaced with alanine residues, 
generated a number of NS5 mutants (R325A, 
R519A-K523A, R769A, K840A-R841A). These mutants 
had high RNA synthesis activity in the recombinant 
protein but delayed or impaired replication when 
introduced into an infectious clone. This suggests that 
the residues could interfere with the other functions 
of NS5 apart from its polymerase activity. 
Interestingly, another mutant (R361A-K370A) showed 
slow-replication phenotype which was correlated 
with its reduced in vitro polymerase activity. Both 
residues 361 and 370 are thought to reside in the 
nuclear localisation site, hence mutations on these 
sites might have caused the NS5 mis-localisation [91]. 
Binding of the stem loop A (SLA) at 5’ UTR to the 
RdRp domain of NS5 was not sufficient to drive the 
polymerase activity; this process required specific 
contacts between the SLA and the RdRp [92]. 
3’ untranslated region (3’ UTR) 
The DENV 3' untranslated region (3 'UTR) is 
approximately 400 nucleotides in length and lacks a 
poly(A) tract [93]. It comprises two stem loops 
xrRNA1 and xrRNA2, strengthened by pseudoknots 
(PK 1 and 2) in Domain I (variable region). Domains II 
and III consist of two dumbbell (DB) structures and a 
stem loop (SL) which are more conserved [94]. The 
two dumbbell structures DB1 and DB2 have the 
tendency to form two potential pseudoknots between 
identical five-nucleotide terminal loops 1 and 2 (TL1 
and TL2) and their complementary pseudoknot 
motifs, PK2 and PK1. Manzano et al. [95] created a 
deletion of five nucleotides within the TLl and TL2 in 
the 5' DB and 3' DB, respectively. Consequently, the 
viral translation rate was reduced by 60% in the 
TLl/TL2 double deletion mutant. This suggested that 
TLl acted synergistically with TL2 in viral translation 
[95]. Proutski et al. [96] showed that the length of 
sequence deletion is inversely correlated with 
infectivity. They also suggested that the structure 
rather than sequence is important for 3’ UTR function.  
It was recently established that non-coding 
RNAs tend to accumulate during flavivirus infections. 
These non-coding RNAs are known as subgenomic 
flavivirus RNAs (sfRNAs). sfRNAs are the products 
of incomplete viral genome degradation of the viral 3’ 
UTR by the host exonuclease, Xrn1 [97, 98]. In a recent 
study, Filomatori et al. [99] found that by adapting 
DENV-2 in either mosquito or human cell line, 
different patterns of sfRNAs would be produced. The 
shorter variants, sfRNA3 and sfRNA4, were positively 
selected in the mosquito cell line compared to the wild 
type-like longer sfRNA1, which was the main sfRNA 
species detected in human cell line-adapted DENV-2. 
It was demonstrated that sfRNA3 and sfRNA4 were 
produced as the result of stalling degradation just 
upstream of two dumbbell structures, DB1 and DB2, 
respectively within the DENV-2 3’ UTR. Point 
mutations within a stem-loop structure preceding 
DB1 and DB2 were found to be sufficient to emulate 
mosquito-adapted DENV-2 behaviour by generating 
mainly sfRNA3 and sfRNA4. The mutants which 
carried the point mutations, S4 and S6, exhibited 
reduced fitness in human cell lines, induced higher 
type 1 interferon responses and could be easily 
outcompeted by viruses that generate the long 
sfRNA1 [99]. 
Conclusion 
In conclusion, developing a vaccine for DENV is 
arguably a challenging task because DENV infection 
tend to manifest in a more severe form after a 
previous infection with a heterologous DENV 
serotype. Additionally, the four serotypes of DENV 
could also be co-circulating at different prevalence 
rates in the same region and the pattern of DENV 
serotypes circulating in a region could also be vastly 
different from another region [100]. The only available 
vaccine, CYD-TDV, appears to only elicit antibodies 
that are unable to neutralize heterologous DENV 
serotypes. Hence, this has drawn attention to the need 
to understand the underlying mechanism(s) of 
protection conferred by both humoral and cellular 
immunity in the context of a dengue vaccine design. 
Before advancing new LAV against DENV to 
field trials, it might be advantageous to quantitatively 
analyse the molecular determinants of virulence and 
the stability of the mutations in the genome both in 
vitro and in vivo. Each of the monovalent component 
of the potential vaccine strains must also be tested in 
seronegative human volunteers [101]. This review has 
identified a number of conserved molecular 
determinants of virulence in DENV by identifying the 
nucleotides and amino acids responsible for reduced 
DENV virulence in vitro and/or in vivo. Given the 
conserved nature of all the nucleotides and amino 
acids discussed here, it follows that the mutations in 
these nucleotides and amino acids should 
theoretically be able to reduce DENV virulence in all 
four DENV serotypes. We speculate that construction 
of a set of such mutations that are well distributed 
along the DENV genome would be more likely to 
produce a successful vaccine candidate. Maintaining 
the backbone of each DENV serotype and 
incorporating the same exact set of key mutations into 
the genome of each monovalent strain in a tetravalent 
formulation might be the ideal solution to minimise 
the interference between different viral strains. It is 




likely that the chimeric DENV-2 might have 
replicated faster in TV003 due to its DENV-4 
backbone. 
Additionally, maintaining the backbones of all 
the four DENV serotypes is crucial as we now learned 
that CD8+ T cells predominantly target conserved 
non-structural (NS) epitopes of DENV [102, 103] 
while CD4+ T cells target predominantly the capsid, 
NS3 and NS5 epitopes [21]. NS genes are also more 
conserved than structural genes. Hence, it is possible 
that by following our proposed rational vaccine 
design of a multiply-mutated tetravalent DENV 
vaccine, this will induce the production of memory T 
cells that target all the serotypes [20]. Since high levels 
of neutralising antibodies will be elicited, they will be 
able to neutralise the DENV and prevent enhance-
ment of heterotypic virus infection through FcγR- 
bearing cells [104]. This should ensure that the vaccine 
is sufficiently immunogenic regardless of the 
individual’s prior DENV exposure and the infecting 
serotype which in turn will lower the risk of ADE. 
Undoubtedly, this step may require a number of trials 
and errors in order to identify which combinations of 
the mutations could synergistically lead to more 
pronounced reductions in virulence. It should also be 
emphasised that a LAV development against DENV 
will benefit greatly from prominent advancement in 
diagnostics tools as current assays do not easily 
distinguish between serotype-specific antibodies, 
transient and long-lasting heterotypic antibodies 
[105]. Mandatory follow-up studies after the admini-
stration of a DENV LAV are equally as important as it 
is believed that the switch from the protective 
immunity to the cross-reactive, non-neutralising 
heterotopic immunity following a natural DENV 
infection or an incomplete DENV immunisation 
occurs about 1-2 years following the initial infection 
or immunisation [106], a problem that is hoped to be 
solved by the rational design of a DENV LAV. 
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